PROGRAM CHAIR
Patricia K. Coyle, MD, FAAN, FANA
Distinguished Professor of Neurology
Vice Chair for Academic Affairs
Director, Stony Brook MS Comprehensive Care Center
Stony Brook University Hospital
Stony Brook, New York
PROGRAM OVERVIEW
Multiple sclerosis is a chronic, immune-mediated disease of the central nervous system that leads to progressive neurological disability and significant reductions in a patient’s quality of life. While the diagnosis of MS has improved, difficulties remain in recognizing certain forms of MS and selecting the appropriate treatment approach. The treatment landscape for MS has rapidly evolved over the past two decades to include a number of disease-modifying therapies, which, while highly significant in their ability to slow disease progression and improve quality of life, nonetheless still face challenges related to suboptimal implementation and adherence. This program will discuss the pathophysiology of MS and its treatment implications, review current data on DMTs, describe evidence- and guideline-based treatment strategies, and help clinicians incorporate shared decision-making and collaborative care to improve outcomes in patients with MS.
TARGET AUDIENCE
This initiative is designed to meet the educational needs of neurologists, neuroimmunologists, nurse practitioners, and physician assistants involved in the diagnosis and management of patients with multiple sclerosis.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the pathophysiology of multiple sclerosis (MS) and its implications for evolving treatment strategies
- Evaluate clinical data on current and investigational disease-modifying therapies (DMTs) and apply best practices for selecting appropriate treatments based on emerging efficacy and safety endpoints
- Develop treatment approaches to prevent or manage adverse effects associated with DMTs
- Implement evidence-based practices, including shared decision-making and collaborative care, to improve outcomes for patients with MS
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Patricia K. Coyle, MD, FAAN, FANA | Consulting fees/advisory boards: Accordant, Amgen, GlaxoSmithKline, Horizon Therapeutics, Novartis, Sanofi Genzyme Contracted research/grant support: Cleveland Clinic, CorEvitas LLC, Genentech/Roche, NINDS, Sanofi Genzyme May reference the following off-label or investigational uses: BTK inhibitors, CNS repair strategies |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Dan DaSilva, Accreditation and Outcomes Coordinator, has nothing to disclose.
- Shannon Mutch, MS, RN, OCN, Has nothing to disclose
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Lauren Bartunek, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Savannah Barron, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: April 28, 2026
EXPIRATION DATE: April 28, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
